Skip Navigation
Archive

NIAID Archive

Important note: Information on this page was accurate at the time of publication. This page is no longer being updated.
​​
NIH HHS News Release Logo
National Institute of Allergy and
Infectious Diseases (NIAID)
http://www.niaid.nih.gov

FOR IMMEDIATE RELEASE
Tuesday, October 26, 2004

Media Contact:
Jennifer Wenger
(301) 402-1663
niaidnews@niaid.nih.gov
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

News Advisory

NIAID Media Roundtable: On the Frontlines of Flu Research

WHAT

As concerns about the flu dominate the headlines, please join us as Anthony S. Fauci, M.D., NIAID director, briefs the media about frontline laboratory and clinical research, including

  • future technologies for the development and manufacture of vaccines, including reverse genetics, cell-culture techniques and recombinant proteins
  • NIAID-supported clinical trials  to study herd immunity and the head-to-head efficacy of different vaccines
  • new diagnostic techniques for rapidly detecting avian flu strains in the event of a pandemic

The event will also serve to launch NIAID’s updated and expanded Focus on Flu Web site, spotlighting cutting-edge NIAID-supported research and graphics that illuminate concepts important to understanding influenza research such as reverse genetics and antigenic shift and drift.

Following the briefing, Dr. Fauci and other NIAID staff will take questions from the audience.

WHO

Anthony S. Fauci, M.D., NIAID director

Brian Murphy, M.D., co-chief, NIAID Laboratory of Infectious Diseases

Kanta Subbarao, M.D., senior investigator, Respiratory Viruses Section, NIAID Laboratory of Infectious Diseases

Linda Lambert, Ph.D., acting chief, NIAID Division of Microbiology and Infectious Diseases (DMID), Influenza, SARS, and Related Viral Respiratory Diseases Section

Cristina Cassetti, Ph.D., program officer, NIAID DMID Influenza, SARS, and Related Viral Respiratory Diseases Section

Maria Giovanni, Ph.D., chief, NIAID DMID Genomics and Technology Development Section

WHEN

Monday, Nov. 15, 10:30 – 11:30 a.m. Eastern Time

WHERE

NIH Campus, Natcher Conference Center, Room E1/E2 Bethesda, MD

Attendees are strongly encouraged to use the Metro. The NIH campus can be easily accessed via the Medical Center stop on the Metro’s Red Line. For information on transportation to and parking and security at NIH, go to http://www.nih.gov/about/visitorsecurity.htm.

REGISTER

Advanced registration is requested.  To register, contact Jennifer Wenger or Laurie K. Doepel at (301) 402-1663, or e-mail jwenger@niaid.nih.gov. Individuals with disabilities who need Sign Language Interpreters or reasonable accommodation to participate in this roundtable should contact Jennifer Wenger or Laurie K. Doepel. Such requests should be made at least 5 days in advance of the event.


NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH...Turning Discovery Into Health ®

back to top


Archive

NIAID Archive

Important note: Information on this page was accurate at the time of publication. This page is no longer being updated.
​​​​

Last Updated October 27, 2004